Raymond James Downgrades ChemoCentryx to Market Perform

Benzinga Newsdesk Aug 5, 2022 4 years ago

NewsDowngradesAnalyst Ratings

Raymond James analyst Steven Seedhouse downgrades ChemoCentryx (NASDAQ:CCXI) from Strong Buy to Market Perform.